In a welcome move, BioNTech ADR saw its Relative Strength Rating rise from 63 to 72 on Wednesday.
This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if BioNTech ADR can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
BioNTech ADR is trying to complete a consolidation with a 131.49 buy point. See if the stock can break out in volume at least 40% above average.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 29%, compared to 0% in the prior report. Revenue increased from -25% to 46%.
BioNTech ADR holds the No. 116 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!